Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Directorate Change

9 Feb 2021 07:00

RNS Number : 3822O
Halma PLC
09 February 2021
 

Halma plc ("Halma")

 

Halma appoints Dame Louise Makin as its next Chair

 

Halma, the FTSE 100 global group of life-saving technology companies, today announces the appointment of Dame Louise Makin as its next Chair.

 

Louise is joining the Board today as an independent Non-Executive Director and Chair Designate. She will join the Nomination and Remuneration committees. Louise will replace Paul Walker as Chair in July 2021, when he steps down from the Board after eight years in that role, as previously announced.

 

Louise has a distinguished career in business as a chief executive and board director, working across multiple sectors.

 

For 15 years Louise was Chief Executive Officer of BTG plc, the international specialist healthcare company. Louise led the transformation of the company through a combination of organic growth and acquisitions, during which its market capitalisation increased from $150m to $4.2bn, before its sale to Boston Scientific in 2019.

 

Louise has broad experience as a board member. She is currently a Non-Executive Director of Theramex Ltd, a pharmaceutical company, Atotech Ltd, a specialty chemicals company, and of Intertek Group plc, the FTSE 100 testing and certification group; a position she will step down from in June 2021. She has previously served as a Non-Executive Director of Premier Foods plc and Woodford Patient Capital Trust plc, and as a director of several not-for-profit organisations.

 

Louise said: "I am delighted to be joining Halma as Chair. Halma is driven by its strong purpose - to grow a safer, cleaner, healthier future for everyone, every day. This couldn't be more relevant to the world we are living in today and I look forward to working with Andrew Williams and the rest of the Halma Board to deliver on this."

 

Andrew Williams, Halma Group Chief Executive, said: "I look forward to working with Louise as Halma's next Chair. She brings tremendous experience and is an excellent cultural fit with Halma and its purpose. She will build on Paul's eight years as Chair and will maintain Halma's track record of stable, long term leadership."

 

There are no further details to be disclosed for Dame Louise Makin under Listing Rule 9.6.13 R.

 

For further information, please contact:

 

Halma plc

Andrew Williams, Group Chief Executive

+44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations

+44 (0)7776 685948

Clayton Hirst, Director of Corporate Affairs

+44 (0)7384 796013

MHP Communications

Andrew Jaques / Giles Robinson

+44 (0)20 3128 8788

 

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

Notes

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: improving food and water quality, and monitoring air pollution.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2021, Halma was named Britain's Most Admired Company by Management Today.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAZZGGZLRNGMZM
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.